Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46690 | 0.88 | FFAR1 (0.59) | FFAR1FFAR4MMP12MMP13RXRA | |
| SCHEMBL13940077 | 0.80 | SLC6A4 (0.45) | MMP12MMP13NR1H4EPHX2 | |
| SCHEMBL46638 | 0.78 | HSD17B10 (0.61) | FFAR1FFAR4MMP12MMP13RXRA | |
| SCHEMBL6439322 | 0.78 | FFAR1 (0.66) | FFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL6469980 | 0.77 | ESR1 (0.46) | FFAR1FFAR4LMNAL3MBTL1 | |
| SCHEMBL6441201 | 0.76 | CYP4F2 (0.41) | FFAR1FFAR4MMP12MMP13NR1H4 | |
| SCHEMBL7407541 | 0.76 | RXRA (0.58) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL712396 | 0.76 | MAPT (0.62) | FFAR1FFAR4MMP12MMP13RXRA | |
| SCHEMBL13939427 | 0.76 | EPHX2 (0.35) | FFAR1FFAR4MMP12MMP13NR1H4 | |
| SCHEMBL7953221 | 0.74 | ALDH1A1 (0.59) | FFAR1FFAR4MMP12MMP13NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| EP-1506959-A2 | Derivatised molecules for mass spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | F3, TBCA, GYPA | FFAR1 4717/4885FFAR4 4231/4885MMP12 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.